heading HKBU KTO HKBU R&D Licensing Limited BEST KTP RISE
Eng
heading heading
知識轉移處
  • 關於 KTO
  • 活動
    • 即將舉行的活動
    • 過去的活動
  • 告示
    • Chief Executive’s Community Project
    • 研究配對補助金計劃
  • 知識轉移
    • 關於知識轉移種子基金
    • 關於提升研究影響力資助基金
    • 知識轉移項目展示
  • 技術轉移
    • 關於技術轉移
    • 項目展示
    • 保護知識產權
      • 專利申請
      • 遞交專利申請
      • 專利維護
      • 商標註冊
      • 版權登記
      • 策略性專利基金
    • 知識產權搜尋
    • MPCF
      • 概念驗證配比基金介紹
      • 概念驗證配比基金項目列表
    • 顧問以及調查工作
    • 浸大科研發展有限公司
  • 創業
    • BEST
      • 關於 BEST
      • BEST Community
      • 線上及線下活動
      • 創業訓練營
      • 機會
      • 項目展示
      • 活動回顧
      • 合作伙伴
    • TSSSU
  • 傳媒中心
    • 出版
    • 畫廊
    • 下載
    • 有用連結
  • 教職員
  • 學生
  • KT Awards
    • 關於 KT Awards
    • Award Recipients of the Year
    • Previous Award Recipients
  • 聯絡我們
  • Change Language: English
Award Recipients of the Year
主頁 > > Award Recipients of the Year

     

 
     
Year 2021/22
Innovation Award

Dr Yu Yuanyuan

Research Assistant Professor, Teaching and Research Division

School of Chinese Medicine

“From functional study of sclerostin loops in bone & cardiovascular system to Orphan Drug Designation”
  Knowledge Transfer Award

  1. Prof Bian Zhaoxiang

Associate Vice-President (Chinese Medicine Development)

  1. Prof Daniel Lai

Dean of Faculty of Social Sciences & Chair Professor of Social Work

  1. Prof Shirley Hung Suet Lin

Head & Professor, Department of Social Work

  1. Mr Cheung Chun Hoi

Assistant Professor of Practice, Clinical Division, School of Chinese Medicine

  1. Communication and Public Relations Office
  2. Estates Office
  3. Finance Office
  4. Human Resources Office
  5. Office of Information Technology

“Project on Caring for Patients of COVID-19: Integrated Model of Online Chinese Medicine cum Emotional Support”
     

Osteogenesis Imperfecta (OI), also known as brittle bone disease, is a rare hereditary bone disease with no effective drugs for treatment. It affects 6 to 7 in 100 thousand people worldwide.  Dr Yu and her team have firstly found that sclerostin loop3 participates in inhibiting bone formation, but not in protecting cardiovascular system. It guides drug discovery direction to address the clinic challenge (a cardiovascular safety concern) of the marked sclerostin antibody in osteoporosis treatment. Further, Dr Yu and her team have identified an oligonucleotide aptamer drug (Apc001) functionally targeting sclerostin loop 3 (the second generation of sclerostin inhibitor) to promote bone formation with low cardiovascular concern for bone anabolic therapy in osteoporosis and osteogenesis imperfect animal models. The therapeutic aptamer Apc001 has been granted Orphan Drug Designation by US FDA (FDA, DRU-2019-6966) in 2019. This is the first drug in Hong Kong and the first aptamer drug in China being granted “orphan drug” designation by FDA.

The team has established a spin-off drug company “Aptacure Therapeutic Limited” based on this project, and supported by the Incu-Bio programme in Hong Kong Science Park. In the long term, it is hoped that the OI patients could obtain the innovative bone anabolic drug to reduce their fracture without cardiovascular risk, especially for patients with cardiovascular history, and further promote good health of Hong Kong with long-term sustainability. Dr Yu’s contributions demonstrate the innovative strengths at HKBU, and raise the good reputation of HKBU both locally and globally.
  Given the recent upsurge in cases amid the COVID-19 pandemic in Hong Kong, HKBU has established a transdisciplinary team of experts and supporting personnel to offer a free and integrated Chinese medicine service, as well as emotional support service to COVID patients, their close contacts and carers. The Chinese Medicine Telemedicine Centre, School of Chinese Medicine, and Social Work Practice and Mental Health Centre, Department of Social Work provide the services. This Project represents an important step towards innovating care model for patients who receive Chinese medicine treatment and more, a new HKBU’s frontier in transdisciplinary collaboration as well as the use of ICT (Information and Communications Technology) to deliver both medical and psychosocial care.

The integrated model started when the Emotional Support Service team of the Department of Social Work joined the Chinese Medicine Telemedicine Centre to become one team on 1 March 2022. The Telemedicine Centre deliver free-of-charge service to patients under quarantine in the community with no critical symptoms who do not require hospitalisation, and the residents and staff members of accredited elderly homes registered for the service. Chinese medicine practitioners of HKBU conduct consultations with patients through WhatsApp video-conferencing, prescribe medicine and provide a medicine dispensing service. Up to 31 March, 0.3 million patients were served.
     
     


查詢

電郵 
kto@hkbu.edu.hk

電話
(852) 3411 8098

傳真
(852) 3411 8093


地址
香港九龍塘聯福道三十四號香港浸會大學逸夫校園思齊樓 825室

© 2022 香港浸會大學知識轉移處版權所有。  私隱聲明
香港浸會大學知識轉移處及所有相關標記、圖標均為商標、註冊商標和服務商標。